Intellia Therapeutics (NTLA) Total Liabilities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Total Liabilities data on file, last reported at $137.8 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $137.8 million, down 33.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $137.8 million (down 33.17% YoY), and the FY2025 annual result was $170.7 million, down 46.49% from the prior year.
• Total Liabilities slipped to $137.8 million in Q1 2026 per NTLA's latest filing, from $170.7 million in the prior quarter.
• Over five years, Total Liabilities peaked at $319.1 million in Q4 2024 and troughed at $137.8 million in Q1 2026.
• A 5-year average of $222.0 million and a median of $220.5 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 45.62% in 2022, then slumped 46.49% in 2025.
• A 5-year view of Total Liabilities shows it stood at $284.5 million in 2022, then retreated by 11.85% to $250.8 million in 2023, then climbed by 27.21% to $319.1 million in 2024, then tumbled by 46.49% to $170.7 million in 2025, then declined by 19.27% to $137.8 million in 2026.
• Business Quant data shows NTLA's Total Liabilities at $137.8 million in Q1 2026, $170.7 million in Q4 2025, and $176.9 million in Q3 2025.